Kura Oncology
Kura Oncology Inc is an American clinical-stage biopharmaceutical company developing precision medicines for the treatment of solid tumors and blood cancers. The company advances targeted small molecule drug candidates including ziftomenib, a menin inhibitor for KMT2A-rearranged and NPM1-mutant acute myeloid leukemia (AML), alongside tipifarnib for HRAS-mutant head and neck squamous cell carcinoma. Principal revenue is driven through research milestone payments, strategic development partnerships, and capital raises ahead of commercial market authorization. Core end markets encompass medical oncology clinics, hematology cancer centers, and acute leukemia prescription patients globally. Kura Oncology holds an innovative position in the biopharmaceutical sector as a developer of precision menin inhibitors for acute myeloid leukemia. The corporation is headquartered in San Diego, California, and its common stock trades on the Nasdaq Global Select Market.
3 of the funds FundTelligence covers report a position in Kura Oncology.
- Legal name
- Kura Oncology Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 3
- Exposure themes
- Precision Medicine & Genomics, Precision Oncology, Precision Therapeutics
Funds holding Kura Oncology
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.06 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.04 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)